(Total Views: 212)
Posted On: 01/10/2019 6:14:24 PM
Post# of 154078
NetworkNewsBreaks – CytoDyn Inc. (CYDY) Appoints New Member to Board of Directors
Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced the appointment of David F. Welch, Ph.D., Founder, Chief Innovation Officer and Director of Infinera Corporation, to the CytoDyn Board of Directors. Dr. Welch has a notable background including strategic planning expertise and broad capital markets experience. As an investor in the company, he appreciates the potential of CYDY’s leronlimab in targeting multiple disease processes. “We are pleased to add Dr. Welch to our Board of Directors. He is a pioneer in the field of optical devices and optical transport with a strong scientific background,” CytoDyn president and CEO Dr. Nader Pourhassan stated in the news release. “Dr. Welch has an inventor’s heart with over 130 patents and 250 published articles to his name. We anticipate he will be a strong contributor to our strategic planning.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced the appointment of David F. Welch, Ph.D., Founder, Chief Innovation Officer and Director of Infinera Corporation, to the CytoDyn Board of Directors. Dr. Welch has a notable background including strategic planning expertise and broad capital markets experience. As an investor in the company, he appreciates the potential of CYDY’s leronlimab in targeting multiple disease processes. “We are pleased to add Dr. Welch to our Board of Directors. He is a pioneer in the field of optical devices and optical transport with a strong scientific background,” CytoDyn president and CEO Dr. Nader Pourhassan stated in the news release. “Dr. Welch has an inventor’s heart with over 130 patents and 250 published articles to his name. We anticipate he will be a strong contributor to our strategic planning.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
